Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial
暂无分享,去创建一个
Jeffrey A. Cohen | E. Stommel | C. Fadul | D. Graber | B. Harris | C. Cogbill | T. Mackenzie | Linda S. Kingman | Jacqueline Y Channon Smith | J. Cohen | Christopher H. Cogbill | Jeffrey A. Cohen | Linda Kingman
[1] D. Roberts,et al. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme , 2008, Journal of Neuro-Oncology.
[2] C. Münch,et al. Thalidomide causes sinus bradycardia in ALS , 2008, Journal of Neurology.
[3] R. Chandra,et al. Elevated Inflammatory Markers in a Group of Amyotrophic Lateral Sclerosis Patients from Northern India , 2008, Neurochemical Research.
[4] M. Cuccia,et al. TNF and sTNFR1/2 plasma levels in ALS patients , 2008, Journal of Neuroimmunology.
[5] R. Michelucci,et al. Neuropathy in multiple myeloma treated with thalidomide , 2007, Neurology.
[6] E. Stommel,et al. Tumor necrosis factor-alpha induces changes in mitochondrial cellular distribution in motor neurons , 2007, Neuroscience.
[7] M. Cudkowicz,et al. Increased incidence of deep venous thrombosis in ALS , 2007, Neurology.
[8] A. Rombos,et al. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[9] M. Beal,et al. Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice , 2006, Journal of the Neurological Sciences.
[10] J. Julien,et al. Absence of Tumor Necrosis Factor-α Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutations , 2006, The Journal of Neuroscience.
[11] D. Cleveland,et al. ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.
[12] J. Kira,et al. Intrathecal Upregulation of Granulocyte Colony Stimulating Factor and Its Neuroprotective Actions on Motor Neurons in Amyotrophic Lateral Sclerosis , 2006, Journal of neuropathology and experimental neurology.
[13] L. Defebvre,et al. Elevated IL-6 and TNF-α levels in patients with ALS: Inflammation or hypoxia? , 2005, Neurology.
[14] M. Baccarani,et al. Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma , 2005, European journal of haematology.
[15] Gian Domenico Borasio,et al. Individual quality of life is not correlated with health-related quality of life or physical function in patients with amyotrophic lateral sclerosis. , 2004, Journal of palliative medicine.
[16] P. Bongioanni,et al. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. , 2004, The Cochrane database of systematic reviews.
[17] G. Cavaletti,et al. Thalidomide sensory neurotoxicity , 2004, Neurology.
[18] Scott Ferrell,et al. Message and protein-level elevation of tumor necrosis factor α (TNFα) and TNFα-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis , 2003, Neurobiology of Disease.
[19] D. Schoenfeld,et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis , 2003, Neurology.
[20] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[21] G. Nicholson,et al. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation , 2002, Journal of neurology, neurosurgery, and psychiatry.
[22] Paul Alan Cox,et al. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. , 2002, Neurology.
[23] G. Sobue,et al. Differential expression of inflammation‐ and apoptosis‐related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis , 2002, Journal of neurochemistry.
[24] D. Schoenfeld,et al. Effect of neurophilin ligands on motor units in mice with SOD1 ALS mutations , 2001, Neurology.
[25] Robert Kapsa,et al. Presymptomatic motor neuron loss and reactive astrocytosis in the SOD1 mouse model of amyotrophic lateral sclerosis , 2001, Muscle & nerve.
[26] J. Elliott. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. , 2001, Brain research. Molecular brain research.
[27] G. Rosoklija,et al. Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis , 2001, Annals of neurology.
[28] N. Latov,et al. Detection of Anti-Gm1 Ganglioside Antibodies in Patients with Neuropathy by a Novel Latex Agglutination Assay , 2000, Journal of immunoassay.
[29] G. Mora,et al. Circulating levels of tumour necrosis factor-α and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis , 2000, Neuroscience Letters.
[30] A. Hyman,et al. Tumor Necrosis Factor Induces Hyperphosphorylation of Kinesin Light Chain and Inhibits Kinesin-Mediated Transport of Mitochondria , 2000, The Journal of cell biology.
[31] P. Stieg,et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. , 2000, Science.
[32] M. Gurney,et al. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .
[33] M. Bellomo,et al. Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration. , 1998, European cytokine network.
[34] W. Fiers,et al. The 55-kDa Tumor Necrosis Factor Receptor Induces Clustering of Mitochondria through Its Membrane-proximal Region* , 1998, The Journal of Biological Chemistry.
[35] J. Niland,et al. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases , 1998, Journal of the Neurological Sciences.
[36] A Hirano,et al. Neuropathology of ALS , 1996, Neurology.
[37] D. Schiffer,et al. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis , 1996, Journal of the Neurological Sciences.
[38] S. Sasaki,et al. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis , 1996, Neurology.
[39] Robert H. Brown,et al. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice , 1995, Cell.
[40] B. Brooks,et al. El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.
[41] G. Kaplan,et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.
[42] G. Sobue,et al. Amyotrophic lateral sclerosis. Lack of central chromatolytic response of motor neurocytons corresponding to active axonal degeneration. , 1983, Archives of neurology.
[43] Hiroshi Tsukagoshi,et al. Morphometric quantification of the cervical limb motor cells in controls and in amyotrophic lateral sclerosis , 1979, Journal of the Neurological Sciences.
[44] M. Sinaki,et al. Rehabilitation techniques for patients with amyotrophic lateral sclerosis. , 1978, Mayo Clinic proceedings.
[45] Dong-Kug Choi,et al. Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis , 2006, The Journal of Neuroscience.
[46] L. Defebvre,et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? , 2005, Neurology.
[47] T. Miyatake,et al. Morphometry of the degenerative process in the hypoglossal nerves in amyotrophic lateral sclerosis , 2004, Acta Neuropathologica.
[48] Scott Ferrell,et al. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. , 2003, Neurobiology of disease.
[49] K. Hensley,et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. , 2002, Journal of neurochemistry.
[50] M. Gurney,et al. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. , 1998, Glia.